It starts with a single mosquito bite. A few days later: high fever, shaking chills, and flu-like symptoms. For millions of people in Pakistan, Africa, and Southeast Asia, Malaria is not just a sickness; it is a deadly threat.
At Wnsfeild Pharmaceuticals, we are on the front lines of this battle. Our Anti-Malarial Segment is dedicated to producing treatments that are fast-acting, effective, and accessible to the communities that need them most.
Despite modern medicine, Malaria remains a global emergency. The parasite (Plasmodium) destroys red blood cells, leading to severe anemia and organ failure if left untreated.
The biggest challenge today is Drug Resistance. In many parts of the world, the malaria parasite has learned to survive older medications like Chloroquine. This is why the World Health Organization (WHO) now recommends ACTs (Artemisinin-based Combination Therapies).
We manufacture advanced anti-malarials designed to hit the parasite hard and fast. Whether it is Artemether or Lumefantrine based therapies, our goal is “Parasite Clearance.”
We focus on:
While our medicines provide the cure, prevention is the first defense.
We envision a world free of Malaria. Until then, we will keep manufacturing the weapons to fight it.
Protect your family from Malaria.
Leave a Reply